173 related articles for article (PubMed ID: 17428784)
1. Structure of the human lung cytochrome P450 2A13.
Smith BD; Sanders JL; Porubsky PR; Lushington GH; Stout CD; Scott EE
J Biol Chem; 2007 Jun; 282(23):17306-13. PubMed ID: 17428784
[TBL] [Abstract][Full Text] [Related]
2. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
DeVore NM; Scott EE
J Biol Chem; 2012 Aug; 287(32):26576-85. PubMed ID: 22700965
[TBL] [Abstract][Full Text] [Related]
3. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes.
DeVore NM; Smith BD; Wang JL; Lushington GH; Scott EE
Drug Metab Dispos; 2009 Jun; 37(6):1319-27. PubMed ID: 19251817
[TBL] [Abstract][Full Text] [Related]
4. Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK.
Xu Y; Shen Z; Shen J; Liu G; Li W; Tang Y
J Mol Graph Model; 2011 Sep; 30():1-9. PubMed ID: 21680215
[TBL] [Abstract][Full Text] [Related]
5. Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes.
DeVore NM; Smith BD; Urban MJ; Scott EE
Drug Metab Dispos; 2008 Dec; 36(12):2582-90. PubMed ID: 18779312
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
Megaraj V; Zhou X; Xie F; Liu Z; Yang W; Ding X
Carcinogenesis; 2014 Jan; 35(1):131-7. PubMed ID: 23917075
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
9. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
10. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol.
Kramlinger VM; von Weymarn LB; Murphy SE
Chem Biol Interact; 2012 May; 197(2-3):87-92. PubMed ID: 22486895
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants.
Shimada T; Murayama N; Kakimoto K; Takenaka S; Lim YR; Yeom S; Kim D; Yamazaki H; Guengerich FP; Komori M
Xenobiotica; 2018 Jun; 48(6):565-575. PubMed ID: 28648140
[TBL] [Abstract][Full Text] [Related]
12. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
13. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
14. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13.
Jalas JR; Ding X; Murphy SE
Drug Metab Dispos; 2003 Oct; 31(10):1199-202. PubMed ID: 12975327
[TBL] [Abstract][Full Text] [Related]
15. Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation.
He XY; Shen J; Hu WY; Ding X; Lu AY; Hong JY
Arch Biochem Biophys; 2004 Jul; 427(2):143-53. PubMed ID: 15196988
[TBL] [Abstract][Full Text] [Related]
16. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.
Pouyfung P; Prasopthum A; Sarapusit S; Srisook E; Rongnoparut P
Drug Metab Pharmacokinet; 2014; 29(1):75-82. PubMed ID: 23903410
[TBL] [Abstract][Full Text] [Related]
18. Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.
Blake LC; Roy A; Neul D; Schoenen FJ; Aubé J; Scott EE
Pharm Res; 2013 Sep; 30(9):2290-302. PubMed ID: 23756756
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2A13 active site mutation N297A on metabolism of coumarin and tobacco-specific nitrosamines.
Schlicht KE; Berg JZ; Murphy SE
Drug Metab Dispos; 2009 Mar; 37(3):665-71. PubMed ID: 19074523
[TBL] [Abstract][Full Text] [Related]
20. The Influence of Tobacco Smoke/Nicotine on CYP2A Expression in Human and African Green Monkey Lungs.
Gao Y; Miksys S; Palmour RM; Tyndale RF
Mol Pharmacol; 2020 Dec; 98(6):658-668. PubMed ID: 33055223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
